Joseph J. Ferra Jr - Dec 16, 2023 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ Robert Yang, Attorney-in-Fact
Stock symbol: ELEV
Transactions as of: Dec 16, 2023
Transactions value $: -$2,434
Form type: 4
Date filed: 12/19/2023, 04:15 PM
Previous filing: Sep 19, 2023
Next filing: Feb 20, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ELEV	Common Stock	Options Exercise		+12.6K	+17.92%		82.7K	Dec 16, 2023	Direct	F1
transaction	ELEV	Common Stock	Tax liability	-$2.43K	-4.77K	-5.77%	$0.51	77.9K	Dec 16, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELEV	Restricted Stock Unit	Options Exercise	$0	-12.6K	-14.29%	$0.00	75.4K	Dec 16, 2023	Common Stock	12.6K		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2	25% of the RSUs vested on June 16, 2022, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F3	The RSUs do not expire; they either vest or are canceled prior to the vesting date.